SUGLETS® Sugar Spheres
For All Round Consistency and Robustness
Your choice for drug layering applications
Multiparticulate drug delivery systems are increasing as pharmaceutical companies seek to improve clinical effectiveness. Sugar spheres, as a starting substrate, provide a reliable platform for drug loading.
SUGLETS®, Sugar Spheres from Colorcon are uniform drug layering pellets, made of sucrose and starch, for sustained or extended release dosage forms. With low friability, consistent sphericity, tight particle size control and high batch-to-batch uniformity, Suglets are ideal for drug loading applications.
Product LiteratureGeneral Information Product Brochure Published Posters Published White Papers / Articles
Tech Bulletin: Suglets®View and Download Send by Email
More Than Monograph: control of particle size, sphericity and friability for consistent product and release profiles
Suglets® Product Information BrochureView and Download Send by Email
AAPS 2014 - Evaluation of a Process Relevant Method for Determining the Robustness of a Sugar Sphere Drug Layering SubstrateView and Download Send by Email
Evaluation of the mechanical robustness of sugar spheres using the oscillating friability method.
AAPS 2015 - Effect of Coating Weight Gain and Pore-Former Level on Drug Release with a Fully Formulated Ethylcellulose Barrier Membrane Coating SystemView and Download Send by Email
AAPS 2015 - Feasibility of Taste-Masking a Highly Soluble Drug via Powder Layering with Fine Particle EthylcelluloseView and Download Send by Email
AAPS 2015 Poster Reprint - Demonstrates the feasibility of ETHOCEL FP powder layering, onto drug loaded Suglets, as a highly efficient taste-masking technology.
AAPS 2016 Optimization of Extrusion Spheronization Process for Multiparticulates via Design of ExperimentsView and Download Send by Email
In this DOE, extrusion spheronization resulted in high sphericity and low friability product, however, waste was also a consideration. Utilizing commercially available sugar spheres, such as SUGLETS®, could result in more consistent and robust multiparticulates.
AAPS 2017 - My Dosage Design Tool Predicts, Process Analytical Technology Confirms Film Thickness of Fully Formulated Aqueous and Organic Ethylcellulose CoatingView and Download Send by Email
AAPS 2020 - Evaluation of Various Formulations and Processes on Barrier Membrane Coating of a BCS Class 1 Drug with Aquacoat® ECD-30View and Download Send by Email
AAPS 2020 - In Vitro Evaluation of an Enteric Coating System for Esomeprazole Delayed Release Multiparticulates for Administration Through Nasogastric TubeView and Download Send by Email
AAPS 2020 - Investigating the Use of Absolute Exhaust Humidity Control as a Control Parameter for Multiparticulate CoatingView and Download Send by Email
AAPS 2020 - Postprandial Enteric Performance of Enteric Coated Omeprazole Multiparticulate SystemsView and Download Send by Email
AAPS 2021 - Drug Release Stability of Propranolol Hydrochloride ER Multiparticulates using Ethylcellulose DispersionsView and Download Send by Email
CRS 2008 - Influence of Solvent Type on ER Coating with Ethylcellulose Barrier MembranesView and Download Send by Email
Influence of solvent combinations on EC solution viscosity and drug release from coated beads
CRS 2008 - Investigation of Venlafaxine HCl Release from Extruded and Spheronized Beads Coated with Ethylcellulose using Organic or Aqueous Coating SystemsView and Download Send by Email
Organic application of EC on venlafaxine HCl extruded and
spheronized beads resulted in a consistent drug release
CRS 2009 - Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane Coated MultiparticulatesView and Download Send by Email
ADS adapted from 2009 CRS poster,The Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane Coated Multiparticulates
CRS 2009 - Influence of Molecular Weight on Drug Release from Ethylcellulose Barrier Membrane MultiparticulatesView and Download Send by Email
Drug release is retarded with increasing molecular weight (viscosity) of EC
CRS 2009 - Influence of Plasticizer Type and Level on Drug Release from Ethylcellulose Barrier Membrane MultiparticulatesView and Download Send by Email
Type and amount of plasticizer can be used as an effective tool to tailor drug release.
CRS 2010 - Influence of Pore-Former on Drug Release from Ethylcellulose Coated MultiparticulatesView and Download Send by Email
Multiparticulate beads coated with ethylcellulose from an organic solution
CRS 2010 - Stability of a Sparingly Soluble BCS Class I API Ethylcellulose Coated MultiparticulateView and Download Send by Email
Investigating the long term stability, curing effects and release kinetics of a sparingly soluble BCS Class I API, layered on nonpareil beads and coated with Surelease.
CRS 2011 - Influence of Dissolution Media pH on Drug Release from Ethylcellulose Coated MultiparticulatesView and Download Send by Email
Comparative evaluation in gastric and intestinal pH media for ionic or non-ionic drugs
CRS 2011 - Influence of Drug Solubility on Release from Ethylcellulose Barrier Membrane Coated MultiparticulatesView and Download Send by Email
Solvent coateding lead to slower drug release than when coated with aqueous dispersion and drug release rate increased with addition of hypromellose as a pore-former
CRS 2016 - Compositional and Performance Stability of a Fully Formulated EthylcelluloseView and Download Send by Email
The purpose of this work was to investigate the compositional stability and controlled release performance of Opadry® EC, ethylcellulose organic coating system, under intermediate and accelerated storage conditions for 6 months.
CRS 2016 - Study of Dose-Weight Proportionality in Extended Release Multiparticulate Systems DifferentView and Download Send by Email
Acetaminophen (APAP) layered sugar spheres (Suglets) were coated with an ethylcellulose barrier membrane using fluid bed coater. Different doses of the coated APAP multiparticulates were tested for dose-weight proportionality; drug release profiles were compared.
CRS 2016 - Why Choose Small Sugar SpheresView and Download Send by Email
The benefits of choosing larger sugar spheres as the starting substrate for modified release multiparticulate applications.
CRS 2021 - Evaluation of Formulated Ethylcellulose Aqueous Dispersions to Develop Controlled Release Multiparticulate Formulation of Freely Soluble Drug, Propranolol HydrochlorideView and Download Send by Email
Published White Papers / Articles
Bitter to Better: Formulation Strategies for Effective Taste MaskingView and Download Send by Email
April 2018 Article Tablets and Capsules Magazine, Author Charles Vesey
CRS 2021 - Impact of Bottom Spray Fluid Bed Processing on Barrier Membrane Coated Drug Layered Pellets Using an Aqueous Ethylcellulose PseudolatexView and Download Send by Email
The selection of the right sugar sphere is a crucial part of the formulation, so it’s important to understand the critical success factors for drug loading:
- Surface roughness and sphericity to ensure uniform application
- Reliable and reproducible uniformity for batch-to-batch consistency
- Range of particle sizes to meet different dose levels
- Low friability and hardness to withstand the rigors of processing
- Available in a range of sizes
Suglets specifications comply with the current version of the USP/NF and PhEur, and are in compliance with applicable excipient GMP requirements.
With two manufacturing sites, both ISO9001 compliant and dedicated to pharmaceutical production of sugar spheres, you can be confident that Suglets meet the premium quality expected from a highly reputable supplier of pharmaceutical excipients. Studies demonstrate the interchangeability of quality and performance and continuous supply is secured with the two interchangeable manufacturing sites. A robust Business Continuity Plan is in place.
Contact Colorcon to find out why SUGLETS should be your first choice for consistent quality!
Colorcon can help to reduce your project time by providing the right solution through excipient selection and process guidance.
Lower total cost and reduce time to market
Life cycle management through modified delivery profiles and product line extensions
Reduce medication errors and improve patient adherence
Stable and consistent product performance
Track and trace